Absent, small, or homeotic 1-like (ASH1L) mRNA 3' untranslated region (ASH1L mRNA 3'UTR)

Absent, small, or homeotic 1-like (ASH1L) is a histone methyltransferase that mediates the mono- and dimethylation of Lysine 36 on Histone H3 (H3K36), a modification generally associated with active gene transcription (UniProt: Q9NR48). The 3' untranslated region (3'UTR) of the ASH1L mRNA is a critical regulatory segment that contains binding sites for various microRNAs and RNA-binding proteins, which control the stability and translation of the ASH1L transcript (PubMed: 25605338). Dysregulation of ASH1L is implicated in several diseases; for instance, its overexpression promotes leukemogenesis in acute myeloid leukemia (AML) and is linked to progression in prostate and breast cancers (PubMed: 28235144). Conversely, ASH1L haploinsufficiency or loss-of-function mutations are strongly associated with neurodevelopmental disorders, particularly autism spectrum disorder (ASD) (PubMed: 30104398). Targeting the ASH1L mRNA 3'UTR with antisense oligonucleotides (ASOs) or microRNA mimics (such as miR-142-3p) offers a therapeutic pathway to modulate ASH1L protein levels (PubMed: 25605338). In oncology, the goal is typically to induce mRNA degradation to reduce oncogenic ASH1L levels, while in neurology, research explores stabilizing the transcript to increase protein expression. This RNA-level targeting provides a specific alternative to small-molecule inhibitors that target the protein's SET or bromodomains. Therapeutic intervention at the RNA level offers a way to bypass the challenges of targeting the large, complex ASH1L protein directly.

Other names

ASH1L 3'UTRKMT2H mRNA 3'UTRASH1-like protein mRNA 3' untranslated regionASH1L 3-prime untranslated region

The mechanism of action involves sequence-specific binding to the 3'UTR to induce mRNA degradation via RNase H recruitment or to inhibit translation through the RNA-induced silencing complex (RISC) (PubMed: 25605338).